Palatin Technologies Inc. to trade as PLTN.PRINCETON, N.J.--(BUSINESS WIRRE)--July 22, 1996--Palatin Technologies, Inc (EBB:PLTN PLTN Platoon PLTN Pembangkit Listrik Tenaga Nuklir (Indonesia) ), previously traded as IFLM IFLM Integrated Farm/Livestock Management , Monday announced that it will trade under the new symbol PLTN beginning with the opening of the market today. Palatin is a developer of proprietary monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing and enabling peptide-based technologies for cancer therapy, diagnostic imaging and ethical drug development. According to Palatin Chairman, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Edward J. Quilt an amendment to the company's charter has become effective that changes the company's name from Interfilm Inc. to Palatin Technologies Inc, increases its authorized common stock and effects a 1-to-10 reverse stock split resulting in 11,539,000 common shares outstanding. As previously announced, Palatin intends to seek listing on the Nasdaq Small Cap. Palatin Technologies is a development stage company dedicated to developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical drug development based upon its proprietary monoclonal antibody, radiolabeling radiolabeling incorporation of a radioactive element into a compound in order to investigate its metabolism, fate and utilization. and enabling peptide platform technologies. CONTACT: Palatin Technologies Inc., Princeton John McDonough, 609/520-1911 or Allen & Caron Inc./SouthCoast Communications Joe Allen/Owen Daley, 714/252-8440 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion